Cargando…

Cross-over—it's a feature, not a bug

Pharmaceutical companies, investigators, regulators, and payers need to work together to adapt standards for drug development that meet the needs of all stakeholders, but first and foremost, benefit cancer patients in the most appropriate way.

Detalles Bibliográficos
Autor principal: Engelsberg, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551154/
https://www.ncbi.nlm.nih.gov/pubmed/26078468
http://dx.doi.org/10.1093/annonc/mdv260